Wilmer Cutler Pickering Hale and Dorr Antitrust Series
PHARMABULLETIN Issue 2, Summer 2005
Abstract
In May 2005, the Food and Drug Administration (FDA) issued draft guidance on the type of information to be posted on its new “Drug Watch” website—a site intended to identify drugs for which it is actively evaluating early safety signals. At this time, the FDA plans only to post information on drug products regulated by the Center for Drug Evaluation and Research, therefore vaccines, blood products and medical devices shall be excluded.
Subject Area
Anti-Trust
Recommended Citation
Mark Heller, Hollie Baker, Robert Barry, James Burling, and Suyong Kim,
"PHARMABULLETIN Issue 2, Summer 2005"
(June 2005).
Wilmer Cutler Pickering Hale and Dorr Antitrust Series.
Wilmer Cutler Pickering Hale and Dorr Antitrust Series.
Working Paper 11.
http://law.bepress.com/wilmer/papers/art11
No readers' reactions have been posted for this article. To submit one, copy the URL for this article (http://law.bepress.com/wilmer/papers/art11) and click here.